RxDoctor Payments Data

Benedict Tiong, MD

Rheumatology · Santa Monica, CANPI 1629415047

Payments from drug & device makers

$3,275in general payments, 2019–2025

Across 14 payments — averaging $233.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • UCB, Inc.$125
  • GSK$125
  • AstraZeneca$125
  • Bristol Myers Squibb$115
  • Johnson & Johnson$52
  • plus $65 from 2 others

What the payments were for

  • Consulting fees$2,40073%
  • Food & beverage$83826%
  • Education$371%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen6$2,668
UCB, Inc.1$125
GSK1$125
AstraZeneca1$125
Bristol Myers Squibb1$115
Johnson & Johnson2$52
Pfizer1$37
AbbVie1$29

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,275 in reported general payments places this provider in the 50th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$107,689
Medicare patients
263
Services billed
1,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib18$168,882
Actemra ActpenTocilizumab31$144,886
Xeljanz XrTofacitinib Citrate22$124,754
EnbrelEtanercept14$114,502
Orencia ClickjectAbatacept18$110,094
Cimzia (2 Pack)Certolizumab Pegol12$86,892
Dupixent SyringeDupilumab12$44,563
Hydroxychloroquine Sulfate149$5,274
Diclofenac Sodium31$4,487
Celecoxib46$3,402
Colchicine43$2,400
Sulfasalazine DrSulfasalazine39$1,867
MethotrexateMethotrexate Sodium52$1,513
Prednisone145$1,118
Pilocarpine Hcl14$930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$29$168,88218 claims
AmgenEnbrel$2,668$114,50214 claims
UCB, Inc.Cimzia (2 Pack)$125$86,89212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 808 rheumatology providers in California.

Other rheumatology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →